Iminod Cream

Introduction

Iminod Cream 5% is an immune response modifier used topically to treat various skin conditions. It is a synthetic compound that stimulates the immune system to fight off abnormal skin cells and pathogens. Iminod Cream 5% is primarily used for its antiviral and antitumor properties in dermatological conditions.

Uses

Iminod Cream 5% is used for:

Treating actinic keratosis, a precancerous skin condition caused by sun exposure.
Managing external genital warts caused by human papillomavirus (HPV).
Addressing superficial basal cell carcinoma in combination with other treatments.

Brand Name	Iminod
Type	Cream
Weight	5%
Generic	Imiquimod
Manufacturer	Ziska Pharmaceuticals Ltd.
Available in	English বাংলা

Mechanism of Action

Iminod Cream 5% acts as an immune response modifier by stimulating the production of cytokines, such as interferon-alpha, in the skin. It activates immune cells like macrophages and T-cells, enhancing the body's ability to fight off abnormal cells and infections. This immune activation helps to clear warts, treat precancerous lesions, and address some skin cancers.

How Long Does It Take to Work?

The therapeutic effects of imiquimod may take several weeks to become evident. For conditions like actinic keratosis and genital warts, improvements are often seen within 2 to 8 weeks of treatment. For basal cell carcinoma, treatment may take up to 12 weeks or longer, depending on the severity and response.

Absorption

Iminod Cream 5% is applied topically and is minimally absorbed through the skin into systemic circulation. The local application ensures that the drug primarily acts at the site of application, minimizing systemic side effects.

Route of Elimination

Iminod Cream 5% is eliminated primarily through metabolic pathways. Because it is used topically, systemic elimination is minimal, and most of the drug is metabolized locally at the site of application. Minimal amounts of the drug may be excreted in the urine.

Dosage

External genital warts in adults: Imiquimod cream should be applied 3 times per week (example: Monday, Wednesday, and Friday; or Tuesday, Thursday, and Saturday) prior to normal sleeping hours, and should remain on the skin for 6 to 10 hours. Imiquimod cream treatment should continue until the clearance of visible genital or perianal warts or for a maximum of 16 weeks per episode of warts.

Imiquimod cream should be applied in a thin layer and rubbed on the clean wart area until the cream vanishes. Only apply to affected areas and avoid any application on internal surfaces. Imiquimod cream should be applied prior to normal sleeping hours. During the 6 to 10 hour treatment period, showering or bathing should be avoided. After this period it is essential that Imiquimod cream is removed with mild soap and water. Application of an excess of cream or prolonged contact with the skin may result in a severe application site reaction. A single use sachet is sufficient to cover a wart area of 20 cm2 (approx. 3 inches2). Sachets should not be re-used once opened. Hands should be washed carefully before and after application of cream. Uncircumcised males treating warts under the foreskin should retract the foreskin and wash the area daily.

Superficial basal cell carcinoma in adults: Apply Imiquimod cream for 6 weeks, 5 times per week (example: Monday to Friday) prior to normal sleeping hours, and leave on the skin for approximately 8 hours. Before applying Imiquimod cream, patients should wash the treatment area with mild soap and water and dry thoroughly. Sufficient cream should be applied to cover the treatment area, including one centimetre of skin surrounding the tumour. The cream should be rubbed into the treatment area until the cream vanishes. The cream should be applied prior to normal sleeping hours and remain on the skin for approximately 8 hours. During this period, showering and bathing should be avoided. After this period it is essential that Imiquimod cream is removed with mild soap and water. Sachets should not be re-used once opened. Hands should be washed carefully before and after application of cream. Response of the treated tumour to Imiquimod cream should be assessed 12 weeks after the end of treatment. If the treated tumour shows an incomplete response, a different therapy should be used. A rest period of several days may be taken if the local skin reaction to Imiquimod cream causes excessive discomfort to the patient, or if infection is observed at the treatment site. In this latter case, appropriate other measures should be taken.

Actinic keratosis in adults: Treatment should be initiated and monitored by a physician. Imiquimod cream should be applied 3 times per week (example: Monday, Wednesday and Friday) for four weeks prior to normal sleeping hours, and left on the skin for approximately 8 hours. Sufficient cream should be applied to cover the treatment area. After a 4-week treatment-free period, clearance of Actinic Keratosis should be assessed. If any lesions persist, treatment should be repeated for another four weeks. An interruption of dosing should be considered if intense local inflammatory reactions occur or if infection is observed at the treatment site. In this latter case, appropriate other measures should be taken. Each treatment period should not be extended beyond 4 weeks due to missed doses or rest periods. If the treated area does not show complete clearance at a follow-up examination about 8 weeks after the last 4-weeks course of treatment, an additional 4-weeks course of Imiquimod treatment may be considered. A different therapy is recommended if the treated lesion(s) shows insufficient response to Imiquimod. Actinic keratosis lesions that have cleared after one or two courses of treatment and subsequently recur can be re-treated with one or two further courses of Imiquimod cream following an at least 12 weeks treatment pause. Before applying Imiquimod cream, patients should wash the treatment area with mild soap and water and dry thoroughly. Sufficient cream should be applied to cover the treatment area, including one centimetre of skin surrounding the tumour. The cream should be rubbed into the treatment area until the cream vanishes. The cream should be applied prior to normal sleeping hours and remain on the skin for approximately 8 hours. During this period, showering and bathing should be avoided. After this period it is essential that Imiquimod cream is removed with mild soap and water. Sachets should not be re-used once opened. Hands should be washed carefully before and after application of cream.

Information applicable to all indications: If a dose is missed, the patient should apply the cream as soon as he/she remember and then he/she should continue with the regular schedule. However the cream should not be applied more than once a day.

Dosage varies based on the condition being treated:

For actinic keratosis: Apply a thin layer to the affected area 2 to 3 times per week, usually for 16 weeks.
For external genital warts: Apply a thin layer to the affected area 3 times a week, usually for up to 16 weeks.
For superficial basal cell carcinoma: Apply a thin layer to the affected area 5 times a week for 6 weeks, sometimes extended based on the response.

Administration

Iminod Cream 5% is administered topically. The affected area should be clean and dry before application. A thin layer of cream is applied and gently rubbed in until fully absorbed. The area should not be covered with a bandage or dressing unless directed by a healthcare provider.

Side Effects

Common side effects include:

Redness and irritation at the site of application.
Dryness, peeling, or flaking of the skin.
Itching or burning sensation.

Serious side effects are rare but may include:

Severe allergic reactions.
Skin ulcers or erosions.
Signs of systemic infection (rare).

Toxicity

Iminod Cream 5% toxicity is generally low due to its topical application and minimal systemic absorption. Overuse or application to large areas may increase the risk of adverse effects, including severe skin irritation. In cases of overdose, discontinue use and consult a healthcare provider.

Precautions

Precautions include:

Avoid application to broken or inflamed skin.
Use with caution in individuals with a history of hypersensitivity to imiquimod or other components.
Monitor for signs of excessive irritation or allergic reactions.

Interaction

Iminod Cream 5%'s interactions with other drugs are minimal due to its topical use and limited systemic absorption. However, avoid combining it with other topical medications that could cause additional irritation or adverse effects.

Disease Interaction

Iminod Cream 5% should be used with caution in individuals with:

Autoimmune diseases, as it could exacerbate these conditions.
Active skin infections, as it may interfere with healing.

Drug Interaction

Drug interactions are generally not a major concern with imiquimod. However, patients should inform their healthcare provider of any other medications being used, especially other topical treatments or systemic drugs.

Food Interactions

There are no significant food interactions with imiquimod. It is applied topically and does not interact with dietary intake.

Pregnancy Use

Iminod Cream 5% is classified as a pregnancy category C drug, meaning that its safety during pregnancy has not been established. It should be used during pregnancy only if the potential benefits outweigh the risks. Consultation with a healthcare provider is recommended.

Lactation Use

Iminod Cream 5%'s use during lactation should be approached with caution. The drug is minimally absorbed systemically, but it is advisable to avoid applying it to areas close to the breast or where the infant might come into contact.

Acute Overdose

Acute overdose with topical imiquimod is unlikely but may result in increased local irritation or inflammation. If a large amount is applied accidentally, wash the area with water and seek medical advice if severe symptoms occur.

Contraindication

Iminod Cream 5% is contraindicated in individuals with:

Known hypersensitivity to imiquimod or any of its components.
Severe skin conditions or infections that could be exacerbated by topical treatment.

Use Direction

Apply imiquimod as directed by a healthcare provider, typically 2 to 3 times per week. Ensure the area is clean and dry before application. Do not apply more than prescribed, and avoid contact with the eyes and mucous membranes.

Storage Conditions

Store imiquimod cream at room temperature, away from moisture and heat. Keep the container tightly closed and out of reach of children.

Volume of Distribution

The volume of distribution for imiquimod is not well-documented due to its minimal systemic absorption from topical use.

Half Life

The half-life of imiquimod is not well-defined, as it is applied topically and its systemic levels are very low. The drug's effects persist due to local immune stimulation.

Clearance

Iloperidone is primarily cleared through metabolism in the skin and, to a lesser extent, through systemic clearance in the liver. The exact clearance rate is not well-defined due to its minimal systemic absorption.

See in details version Iminod Cream 5% also Iminod Cream 5% in bangla